Barclays to Run Expanded Commissions for Cancer for Third Year
Posted by Colin Lambert. Last updated: February 27, 2024
Barclays is preparing for its third annual Commissions for Cancer event from 11-15 March, which supports the The Leukemia & Lymphoma Society (LLS), and this year US equities have been added to the markets that clients can trade to raise money for the good cause.
Clients are invited to trade via select BARX electronic channels during the week the event is on, with the bank donating 75% of net commissions earned globally from the BARX Gator algo platform in FX; $1/mm up to $200,000 for G3 bonds traded electronically; 100% of global agency net commissions generated from self-executed algo flow in futures; and, for the first time, 75% of net commissions generated from US equities electronic flow up to $100,000.
The LLS mission is to cure leukemia, lymphoma, Hodgkin’s disease and myeloma, and improve the quality of life of patients and their families. It funds lifesaving blood cancer research around the world, provides free information and support services, and is the voice for all blood cancer patients seeking access to quality, affordable, coordinated care.
More details can be found here with the funds raised further helping the important work of this cancer research organisation.
